Dare Bioscience, Inc. current report, 14 August 2019

Dare Bioscience, Inc. - Form 8-K Summary

Business Context and Reporting Period

Dare Bioscience, Inc. (Nasdaq: DARE), an emerging growth company incorporated in Delaware, filed this Current Report on August 14, 2019. The filing announces the financial results for the second quarter ended June 30, 2019.

Key Financial Metrics

The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. The filing text itself does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

No specific material changes or comparative financial data are detailed within the body of this Form 8-K. Investors must refer to the attached press release for period-over-period analysis.

Guidance, Outlook, and Risks

The filing includes a standard disclaimer stating that the information furnished under Item 2.02 and in Exhibit 99.1 is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into other filings unless expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in this text.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated August 14, 2019) for actual Q2 2019 financial figures.
  • Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
  • Confirm the trading symbol (DARE) and exchange (Nasdaq Capital Market) for current market data.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.